An economic review of compliance with medication therapy in the treatment of schizophrenia.
about
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaDuration of bed occupancy as calculated at a random chosen day in an acute care ward. Implications for the use of scarce resources in psychiatric care.Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.Medication adherence in schizophreniaChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureA pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance lossSustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational studyLong-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.The heterogeneity of antipsychotic response in the treatment of schizophrenia.Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisPoor response to treatment: beyond medication.Using films as a psychoeducation tool for patients with schizophrenia: a pilot study using a quasi-experimental pre-post design.[Risk factors for treatment adherence in patients with schizophrenia: case-control study].Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes.Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective.Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.Educational interventions for mental health consumers receiving psychotropic medication: a review of the evidence.Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia.Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophreniaInpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.Rethinking antipsychotic formulary policy.Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study.Incidence and factors associated with medication nonadherence in patients with mental illness: a cross-sectional studyCost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approachUnmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Are attitudes towards medication adherence associated with medication adherence behaviours among patients with psychosis? A systematic review and meta analysis.Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.The Cost of Relapse in Schizophrenia.Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.Antipsychotic agents: efficacy and safety in schizophreniaChanges in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US.Perceived risk of relapse and role of medication: comparison between patients with psychosis and their caregivers.Direct transition to long-acting risperidone--analysis of long-term efficacy.Risk factors for readmission in schizophrenia patients following involuntary admission.Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
P2860
Q21260279-445A1426-ADD2-4862-B154-D563741ED150Q24814844-91129AEF-5FDE-4202-8739-227B7636AC53Q25257471-4B904CC0-E61C-487D-8E77-789596584753Q26823655-26B7E0E8-F7F2-41D6-AD71-7C48034A2478Q28728401-5C031E42-E8F3-47B8-BDA8-5F242834C003Q33410397-A191B43C-8C00-4B5F-A3B6-A23DDAFC0A27Q34003858-21973AD6-F79D-4A37-9A90-3357B457D77AQ34293899-3CAEC29F-90A8-4F34-8179-0FFCBE501B9AQ34362623-AEDF6829-FC55-424B-AD0B-6CFF38C48349Q34831046-5AB0DFF5-1AD5-48D4-94AC-FEC222E05830Q34982167-C9AB47EC-EA4E-43D4-BAE6-A88FAABA5819Q35236765-A6334AEE-EF11-48E9-AC1A-BE587B3FFB8DQ35577308-DF31D7CA-5D9A-4938-A9BF-D2AF63B95ECFQ35793302-03103C7B-6C76-4936-8007-C2C0A3E3FEEAQ35965617-65C649DC-5443-4F01-B6A2-FE664435656DQ36168916-BD8188D2-75BC-4399-A917-9A0CC4700E67Q36183650-79D74CE8-3D93-4AAD-B9CF-68317AA07346Q36405653-6D411258-72EC-471A-95C1-1C7D84EB914CQ36626247-01B187C2-F091-48CC-9E04-6EED61826EAAQ36670942-F4EC2C19-F340-466E-9C6A-812D33AE0DCAQ36755049-AFC9C49C-1335-4E67-9E97-9A9D36399CF5Q36798150-30224EDD-DF5D-43C6-BF07-B0605EB0BF5AQ36883316-9DC71530-73DC-4365-957A-472957B0E2C9Q37079066-35EAB6DC-C896-43F1-BEFC-1DEE9CD6AC0EQ37091075-642ED16A-9DA8-40DC-B333-01692BD02E5DQ37185914-7F960D44-F102-4C68-850D-3CCD8FA243D2Q37405519-CB503AD0-95E3-4F7A-BF25-EF724B6E5F1CQ37735808-6E329E04-05C7-4F3A-B5FC-C04778F73E4AQ37896627-72C3DAD5-A5E1-41D1-A0D7-BEC90829CC8DQ37985887-893BACC3-C245-4891-A406-CC9221313287Q38041979-B5D21FD8-476A-4400-B0EE-C86E7A320689Q38632506-9C0893FA-47E2-4DEF-8DDB-2EF27052D546Q38769604-9532F5CA-F505-4A6D-AD74-6B1AE1AC40BFQ41656775-801A9731-AF0E-4832-983E-B2706E84BF5AQ41957512-ED5C9D08-151E-41C2-954E-0C823D4EF7B3Q43948188-9FE7FB5F-9BB1-4799-9FCD-EB68C86F433DQ45384257-A6091CBD-5186-4CA5-B9F6-93D0D441FBB3Q46689236-3955E409-063A-4298-9E4B-5D224F366E62Q47096705-E44276BD-D43F-41AD-B384-FB995F88B027Q47661583-0500151A-9104-471B-9AA8-C5ACBB3BEBAC
P2860
An economic review of compliance with medication therapy in the treatment of schizophrenia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
An economic review of complian ...... he treatment of schizophrenia.
@ast
An economic review of complian ...... he treatment of schizophrenia.
@en
type
label
An economic review of complian ...... he treatment of schizophrenia.
@ast
An economic review of complian ...... he treatment of schizophrenia.
@en
prefLabel
An economic review of complian ...... he treatment of schizophrenia.
@ast
An economic review of complian ...... he treatment of schizophrenia.
@en
P2093
P356
P1433
P1476
An economic review of complian ...... he treatment of schizophrenia.
@en
P2093
Anke Richter
Patricia Thieda
Stephen Beard
P304
P356
10.1176/APPI.PS.54.4.508
P577
2003-04-01T00:00:00Z